What is Allakos?
Allakos Inc. is a biotechnology company focused on developing therapeutics that target immunomodulatory receptors on immune effector cells. These receptors play a critical role in various immune responses, making them key targets for treating conditions such as allergies, inflammatory diseases, and proliferative disorders. The company's primary product candidate, AK006, is currently undergoing Phase I clinical trials for chronic spontaneous urticaria (CSU) and other indications. Founded in 2012 and headquartered in San Carlos, California, Allakos is strategically positioned within the burgeoning biotech landscape, aiming to address significant unmet medical needs through its innovative approach to immune system modulation.
How much funding has Allakos raised?
Allakos has raised a total of $276.4M across 3 funding rounds:
Series A
$42M
Series B
$100M
Stock Offering
$134.4M
Series A (2014): $42M with participation from Novo Ventures, Alta Partners, and RiverVest
Series B (2017): $100M led by Samsara BioCapital, LifeSci Venture Partners, Partner Fund Management, Redmile Group, Rock Springs Capital, RiverVest Venture Partners, Roche, Alta Partners, New Enterprise Associates, and 3x5 Partners
Stock Issuance/Offering (2018): $134.4M, investors not publicly disclosed
Key Investors in Allakos
Novo Ventures
Novo Ventures, associated with Novo Holdings, is a significant player in life sciences investment, known for its strategic backing of innovative biotechnology companies.
Alta Partners
Alta Partners is a venture capital firm specializing in healthcare and life sciences, dedicated to supporting entrepreneurs in building impactful companies and focusing on innovative solutions that enhance patient outcomes.
Partner Fund Management
Partner Fund Management is an investment firm that provides capital for companies, likely focusing on strategic growth and development within the life sciences sector.
What's next for Allakos?
With the recent infusion of $134.4M in a major strategic investment, Allakos is poised for accelerated development and potential commercialization of its therapeutic candidates. This substantial backing, part of its overall $276.4M in capital, signals strong investor confidence in the company's scientific approach and market potential. The funding is anticipated to support ongoing clinical trials, expand research and development efforts, and potentially scale manufacturing capabilities. Allakos's focus on immunomodulatory receptors places it at the forefront of precision medicine, with the potential to significantly impact patient outcomes in a range of immune-related diseases.
See full Allakos company page
